Sign In
Buy PEPG
$1.42
-0.0300 (-2.07%)
At Close: Jun 03, 2026
PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of “Moderate Buy” by Brokerages
03:42am, Saturday, 03'rd Jan 2026
PepGen, Inc. (NASDAQ: PEPG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, Marketbeat Ratings repor
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
10:56am, Wednesday, 10'th Dec 2025
The mean of analysts' price targets for PepGen (PEPG) points to a 75.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
07:00am, Tuesday, 09'th Dec 2025
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
07:00am, Monday, 08'th Dec 2025
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)
03:02am, Sunday, 07'th Dec 2025
Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based o
Analysts Set PepGen, Inc. (NASDAQ:PEPG) Target Price at $10.00
02:34am, Monday, 17'th Nov 2025
PepGen, Inc. (NASDAQ: PEPG - Get Free Report) has been assigned a consensus rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat reports. Two analysts have r
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
07:05am, Wednesday, 12'th Nov 2025
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
07:00am, Wednesday, 12'th Nov 2025
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se
PepGen to Participate in Upcoming Investor Conferences
07:00am, Monday, 03'rd Nov 2025
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se
PepGen: DMD Discontinued, Ways To Go With DM1
06:38pm, Tuesday, 07'th Oct 2025
PepGen Inc. (PEPG) has seen its DM1 trials advance to phase 2 with a great reaction from markets. PEPG discontinued its DMD trials, which explains some of the reduced R&D expenses in the last 3 months
Insiders Snap Up $54M in Biotech and Offshore Driller Stocks
08:45am, Tuesday, 07'th Oct 2025
In the past week or so, some public offerings of stock prompted big insider buying.
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
07:00am, Thursday, 02'nd Oct 2025
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se
BOSTON,--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of
PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles
09:46am, Thursday, 25'th Sep 2025
PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.
PepGen Announces Pricing of $100 Million Public Offering
10:51pm, Wednesday, 24'th Sep 2025
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of s
